PRLD
Prelude·NASDAQ
--
--(--)
--
--(--)
PRLD fundamentals
Prelude (PRLD) released its earnings on Nov 12, 2025: revenue was 6.50M (YoY +116.67%), beat estimates; EPS was -0.26 (YoY +39.53%), beat estimates.
Revenue / YoY
6.50M
+116.67%
EPS / YoY
-0.26
+39.53%
Report date
Nov 12, 2025
PRLD Earnings Call Summary for Q3,2025
- Two Lead Programs in 2026: JAK2V617F inhibitor for MPN and KAT6A degrader for ER+ breast cancer.
- Incyte Deal: $60M upfront, up to $910M total, leveraging Incyte's MPN expertise.
- Selective Degradation: KAT6A degrader avoids dual inhibition toxicity, showing preclinical efficacy.
- Clinical Timelines: JAK2 Phase I H1 2026, KAT6A Phase I H2 2026.
EPS
Actual | -0.45 | -0.47 | -0.58 | -0.66 | -0.71 | -0.63 | -0.58 | -0.63 | -0.6 | -0.58 | -0.54 | -0.45 | -0.45 | -0.42 | -0.46 | -0.43 | -0.37 | -0.42 | -0.41 | -0.26 |
Forecast | -0.4933 | -0.452 | -0.494 | -0.625 | -0.6925 | -0.65 | -0.608 | -0.636 | -0.628 | -0.685 | -0.6333 | -0.5833 | -0.49 | -0.484 | -0.43 | -0.472 | -0.4633 | -0.4667 | -0.4375 | -0.37 |
Surprise | +8.78% | -3.98% | -17.41% | -5.60% | -2.53% | +3.08% | +4.61% | +0.94% | +4.46% | +15.33% | +14.73% | +22.85% | +8.16% | +13.22% | -6.98% | +8.90% | +20.14% | +10.01% | +6.29% | +29.73% |
Revenue
Actual | 0 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | -- | 0 | 3.00M | 4.00M | 0 | 0 | 6.50M |
Forecast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What is the revenue and EPS growth rate for Prelude year over year?What is Prelude's latest dividend and current dividend yield?What is the market's earnings forecast for Prelude next quarter?What is Prelude's gross profit margin?What were the key takeaways from Prelude’s earnings call?What were the key takeaways from Prelude's earnings call?What does Prelude do and what are its main business segments?What factors drove the changes in Prelude's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
